Table 2 Baseline demographic and disease characteristics of the RCTs
From: Interleukin-1β inhibitors for the management of acute gout flares: a systematic literature review
Author | Sex, male (%) | Age range, years, mean (SD) | Disease duration, years, mean (SD) | Number of GFs, mean (SD) | Presence of tophi, % | Reason for prescribing IL-1β inhibitors |
|---|---|---|---|---|---|---|
CAN (N = 4) | ||||||
Schlesinger et al., 2011a [20] | CAN: 82.8%‒100.0% TA: 96.5% | CAN: 49.9 (11.1) to 54.9 (10.8) TA: 52.4 (11.6) | NR | Previous year: CAN: 3.9 (2.6) to 6.8 (8.1) TA: 6.5 (9.9) | NR | NR |
Schlesinger et al., 2011b [21] | CAN 25‒300 mg: 88.9%‒100.0% CAN q4wk: 92.5% CLC: 93.5% | CAN 25‒300 mg: 50.7 (9.7) to 54.4 (12.2) CAN q4wk: 52.8 (10.4) CLC: 52.4 (10.7) | > 10-years, N (%): CAN 25‒300 mg: 15 (27.8) to 24 (43.6) CAN q4wk: 18 (34.0) CLC: 33 (30.6) | Previous year: CAN 25‒300 mg: 3.6 (2.3) to 4.7 (4.5) CAN q4wk: 4.4 (4.1) CLC: 4.3 (3.8) | NR | NR |
Schlesinger et al., 2012 [19] | CAN: 89.3% TA: 93.0% | CAN: 52.3 (11.8) TA: 53.6 (11.5) | > 10-years, N (%): CAN: 69 (30.7) TA: 96 (41.9) | Previous year: CAN: 6.5 (5.6) TA: 6.5 (4.8) | CAN: 28.4% TA: 29.7% | Having contraindications for, intolerance of, or unresponsiveness to NSAIDs and/or CLC |
ANK (N = 2) | ||||||
Janssen et al., 2019 [16] | TaU: 93.3% ANK: 95.3% | TaU: 59.9 (12.7) ANK: 63.4 (12.9) | NR | NR | NR | NR |
Saag et al., 2021 [18] | TA: 87.3% ANK: 85.7%‒87.0% | Median (range): TA: 56.0 (30‒83) ANK: 53.5 (25‒79) to 54.0 (27‒78) | TA: 7.7 (7.6) ANK: 8.6 (7.7) to 9.7 (8.8) | Previous year: TA: 4.4 (2.0) ANK: 4.4 (1.7) to 4.6 (3.4) | TA: 38.2% ANK: 30.4%‒38.9% | Patients had to have non-responsiveness to NSAIDs and CLC or were contraindicated to them |
RL (N = 5) | ||||||
Mitha et al., 2013 [17] | PBO: 93.9% RL: 91.7%‒93.9% | PBO: 51.7 (12.9) RL: 49.0 (11.8) to 52.6 (11.5) | PBO: 9.6 (8.8) RL: 8.7 (7.0) to 12.6 (10.3) | P/Y: PBO: 7.1 (6.9) RL: 6.8 (5.4) to 7.0 (5.7) | PBO: 22.0% RL: 25.0%‒25.6% | NR |
Schumacher et al., 2012a [23] | PBO: 95.2% RL: 97.6% | PBO: 50.1 (11.6) RL: 51.9 (10.6) | PBO: 8.6 (7.0) RL: 10.7 (9.1) | Previous year: PBO: 4.4 (4.0) RL: 4.7 (3.2) | PBO: 14.3% RL: 4.9% | NR |
Schumacher et al., 2012b [22] | PBO: 96.2% RL: 88.8%‒93.8% | PBO: 52.2 (13.6) RL: 51.9 (11.6) to 52.9 (12.5) | PBO: 11.2 (9.4) RL: 9.1 (8.3) to 10.0 (8.3) | P/Y: PBO: 4.6 (3.6) RL: 4.5 (3.6) to 4.6 (2.9) | PBO: 10.1% RL: 9.9%‒12.5% | NR |
Sundy et al., 2014 [24] | PBO: 90.0% RL: 87.0% | PBO: 52.4 (10.6) RL: 52.8 (11.5) | PBO: 10.6 (8.4) RL: 10.7 (9.6) | P/Y: PBO: 6.1 (7.2) RL: 6.0 (6.3) | PBO: 30.9% RL: 28.3% | NR |
Terkeltaub et al., 2013 [25] | PBO + IND: 94.7% RL + IND: 95.9% RL + PBO: 91.8% | PBO + IND: 51.3 (10.9) RL + IND: 48.6 (10.0) RL + PBO: 51.0 (10.8) | PBO + IND: 8.8 (6.7) RL + IND: 11.0 (7.9) RL + PBO: 10.2 (9.9) | P/Y: PBO + IND: 4.8 (5.2) RL + IND: 5.5 (5.3) RL + PBO: 5.2 (4.8) | PBO + IND: 13.3% RL + IND: 16.2% RL + PBO: 17.8% | NR |